nach oben

Erschienen in:

01.03.2023 | Case report

Durvalumab/pembrolizumab

Diabetes mellitus, hyperthyroidism and ketoacidosis: 2 case reports

Einloggen, um Zugang zu erhalten

Author Information

An event is serious (based on the ICH definition) when the patient outcome is&colon;

…

Diaz-Trastoy O, et al. Diabetes mellitus associated to treatment with inmunitary checkpoint inhibitors. Medicina Clinica 159: e19-e20, No. 3, 12 Aug 2022. Available from: URL: http://doi.org/10.1016/j.medcli.2022.02.011 [Spanish; summarised from a translation]

Titel: Durvalumab/pembrolizumab
Diabetes mellitus, hyperthyroidism and ketoacidosis: 2 case reports
Publikationsdatum: 01.03.2023
Verlag: Springer International Publishing
Erschienen in: Reactions Weekly / Ausgabe 1/2023
Print ISSN: 0114-9954
Elektronische ISSN: 1179-2051
DOI: https://doi.org/10.1007/s40278-023-34815-x